Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15213


Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells. Combining calcitriol with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of calcitriol combined with carboplatin in treating patients who have advanced solid tumors.


Study summary:

OBJECTIVES: - Determine the maximum tolerated doses of calcitriol and carboplatin, when given in combination, in patients with advanced solid tumors. - Determine the toxic effects of this regimen in these patients. - Determine the effect of calcitriol on the pharmacokinetics of carboplatin in these patients. - Correlate the pharmacokinetics of carboplatin with the myelosuppression following this regimen in these patients. - Determine the safety and efficacy of this regimen in patients with malignant glioma. OUTLINE: This is a dose-escalation study. Patients are stratified according to disease (brain tumor vs other solid tumor) and accrued in parallel. Patients are assigned to one of two treatment groups. - Group 1: Patients receive carboplatin IV over 20-30 minutes on day 1 and calcitriol subcutaneously (SC) or orally daily on days 2-4 for the first course only. For subsequent courses, patients receive calcitriol SC or orally daily on days 1-3 and carboplatin IV over 20-30 minutes on day 3. - Group 2: Patients receive calcitriol SC or orally daily on days 1-3 and carboplatin IV over 20-30 minutes on day 3 for the first, third, and subsequent courses. For the second course only, patients receive carboplatin IV over 20-30 minutes on day 1 and calcitriol SC or orally daily on days 2-4. In both groups, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Sequential dose escalation of calcitriol is followed by sequential dose escalation of carboplatin. Cohorts of 3-6 patients receive escalating doses of calcitriol and then carboplatin until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: Approximately 18-50 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed advanced solid tumor that is not curable by standard therapy, including glioma and other brain tumors - Brain metastases allowed following definitive radiotherapy PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - At least 8 weeks Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 mg/dL - SGOT no greater than 4 times normal Renal: - Creatinine no greater than 1.5 mg/dL OR - Creatinine clearance at least 60 mL/min - Creatinine no greater than 2.0 mg/dL - Calcium no greater than 10.5 mg/dL Cardiovascular: - No unstable angina - No symptomatic coronary artery disease Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use 2 forms of barrier contraception AND 1 form of hormonal contraception for at least 1 week before, during, and for at least 2 weeks after study - No active infection - No other concurrent serious condition PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior biologic therapy (regional or systemic) Chemotherapy: - At least 4 weeks since prior chemotherapy Endocrine therapy: - No concurrent glucocorticoids as antiemetics - Concurrent exogenous glucocorticoids allowed for treatment of gliomas or other brain tumors Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy Surgery: - Not specified Other: - Dietary calcium intake of no more than 200-250 mg/day beginning 48 hours before each course and continuing for 7 days - No concurrent dairy products, green leafy vegetables, molasses, baking powder, fortified cereals, and dry peas and beans


NCT ID:

NCT00008086


Primary Contact:

Study Chair
Ramesh K. Ramanathan, MD
University of Pittsburgh


Backup Contact:

N/A


Location Contact:

Pittsburgh, Pennsylvania 15213
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.